Reimagining therapeutic delivery

We’re innovating smart-pill technologies designed to deliver the right dose to the right place, safely.

BioJet™ Oral Therapeutic Delivery Platform

Needle-free, oral delivery of large molecules designed to replace injection for better management of chronic diseases.

Learn More

NaviCap™ Targeted Therapeutic Delivery Platform

Treatment at the site of disease in the GI tract could improve outcomes for patients with inflammatory bowel disease

Learn More

Press Releases

Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth Dec 30, 2024

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Nov 14, 2024

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update Nov 7, 2024

Publications

Single ascending dose results from a Phase 1 clinical trial of BT-600, a combination product of the NaviCap™ targeted oral delivery platform and tofacitinib

October 28, 2024 #NaviCap Targeted Therapeutic Delivery

Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC

May 18, 2024 #NaviCap Targeted Therapeutic Delivery

Evaluation of the pharmacokinetics of GLP-1 receptor agonist delivered through the BioJet™ oral biotherapeutic delivery platform in a porcine model: an update

October 4, 2023 #BioJet Oral Therapeutic Delivery